Completed PHASE2 INTERVENTIONAL 5-arm NCT00112437

A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin K Inhibitor) in the Treatment of Postmenopausal Women With Osteoporosis

Sponsor: Merck Sharp & Dohme LLC

Conditions Osteoporosis

Interventions Calcium Carbonate Odanacatib Placebo Vitamin D3

Updated 8 times since 2017 Last updated: Dec 21, 2017 Started: Jun 24, 2005 Primary completion: Dec 26, 2007 Completion: Jan 20, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Osteoporosis and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Feb 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.